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Abstract
Despite evidence of the clustering of metabolic syndrome components, current approaches for identifying unifying genetic
mechanisms typically evaluate clinical categories that do not provide adequate etiological information. Here, we used data
from 19,486 European American and 6,287 African American Candidate Gene Association Resource Consortium participants
to identify loci associated with the clustering of metabolic phenotypes. Six phenotype domains (atherogenic dyslipidemia,
vascular dysfunction, vascular inflammation, pro-thrombotic state, central obesity, and elevated plasma glucose)
encompassing 19 quantitative traits were examined. Principal components analysis was used to reduce the dimension of
each domain such that .55% of the trait variance was represented within each domain. We then applied a statistically
efficient and computational feasible multivariate approach that related eight principal components from the six domains to
250,000 imputed SNPs using an additive genetic model and including demographic covariates. In European Americans, we
identified 606 genome-wide significant SNPs representing 19 loci. Many of these loci were associated with only one trait
domain, were consistent with results in African Americans, and overlapped with published findings, for instance central
obesity and FTO. However, our approach, which is applicable to any set of interval scale traits that is heritable and exhibits
evidence of phenotypic clustering, identified three new loci in or near APOC1, BRAP, and PLCG1, which were associated with
multiple phenotype domains. These pleiotropic loci may help characterize metabolic dysregulation and identify targets for
intervention.
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Introduction
The metabolic syndrome represents metabolic dysregulation
expressed as the clustering of several physiologic risk factors and is
associated with an increased risk of atherosclerosis and type 2
diabetes [1]. The core metabolic syndrome domains are
abdominal obesity, atherogenic dyslipidemia, elevated blood
pressure, elevated plasma glucose, a pro-thrombotic state, and a
pro-inflammatory state [2], which are represented to varying
degrees in commonly used metabolic syndrome scoring systems
[3–7].
Several lines of evidence support a genetic basis underlying the
core metabolic syndrome domains. Measures of metabolic
domains cluster in families [8] and heritability estimates range
from 16% for systolic blood pressure to 60% for high-density
lipoprotein (HDL) cholesterol [9]. Genome-wide association
(GWA) studies have also identified common variants in CETP,
LPL, APOA5, and GCKR that influence the co-occurrence of
metabolic domain phenotypes [10,11].
Despite evidence of the clustering of metabolic domain
phenotypes, current approaches for identifying unifying genetic
mechanisms (i.e. pleiotropy) remain largely focused on clinical
categories that do not provide adequate etiological information
[12]. As an alternative, a phenomics approach that assembles
coherent sets of phenotypic features that extend across individual
measurements and diagnostic boundaries creates the opportunity
for novel genetic investigations of established biological pathways
and complements the traditional GWA study or candidate gene-
based strategy focused on individual phenotypes [13–15]. In
addition to making use of existing knowledge on process-related
information or pathways, a multi-phenotype phenomics approach
also may provide greater statistical power than analyses of
individual phenotypes [16] and improve the ability to detect
effects of small magnitude [17]. Although several authors have
advocated the use of such strategies [15,18,19], the approach is
implemented infrequently.
This study evaluated evidence of pleiotropy in clustered
metabolic domains using data from five well characterized
population-based studies composed of approximately 20,000
European American and 6,200 African American participants:
the Atherosclerosis Risk in Communities (ARIC) study, the
Coronary Artery Risk Development in Young Adults (CARDIA)
study, the Cardiovascular Health Study (CHS), the Framingham
Heart Study (FHS), and the Multi-Ethnic Study of Atherosclerosis
(MESA). Six phenotype domains (atherogenic dyslipidemia,
vascular dysfunction, vascular inflammation, pro-thrombotic state,
central obesity and elevated plasma glucose) encompassing 19
quantitative traits were examined. After dimension reduction, we
applied a statistically efficient and computationally feasible
multivariate approach that related the phenotype domains to
250,000 imputed SNPs. Our approach, which is applicable to
studies of heritable, clustered interval scale outcomes, identified
several genome-wide significant loci associated with multiple
phenotype domains, which may help characterize metabolic
dysregulation and identify targets for intervention.
Results
After excluding duplicate samples (N=56), first- and second-
degree relatives (N=1,152) in all studies except the family-based
Framingham Heart Study, and individuals identified as genetic
outliers (N=20), there were 19,468 European American and
6,287 African American Candidate Gene Association Resource
Consortium (CARe) participants available for analysis. As
expected, CARDIA participants (mean age: 25 years) had better
cardiovascular health profiles, including lower low density
lipoprotein concentrations, markers of vascular inflammation,
and blood pressure levels when compared to the older cohorts
(Tables S1, S2, S3, S4, S5).
Eight principle components were used to characterize the six
metabolic syndrome trait domains (Figure 1): one principal
component each for vascular dysfunction, elevated plasma glucose,
pro-thrombotic state and central obesity and two principal
components for atherogenic dyslipidemia and vascular inflamma-
tion. Correlation between the principal components, which served
as the eight phenotypes of interest, was modest and consistent
across studies and racial groups. As an example, race- specific
results from the ARIC Study are presented in Tables S6, S7.
ARIC and CARDIA were the only studies with full phenotype
data for all 19 of the variables used to define the metabolic trait
domains. Although apolipoprotein A1 and B measurements were
unavailable in three cohorts, the high correlations with high-
density and low-density lipoprotein concentrations (r.0.70 in
ARIC data, Tables S8, S9) suggested that all five cohorts provided
similar atherogenic dyslipidemia phenotypes. A similarly high
correlation was observed between von Willebrand factor and
factor VIII in the ARIC data, implying a common pro-thrombotic
phenotype in studies missing either measurement. The modest
correlation between systemic markers of inflammation in the
MESA study, which did not measure white blood cell count and
uric acid concentration, suggests that this study may contribute a
slightly different vascular inflammation phenotype. The MESA
study also did not assay factor VII, suggesting that this study also
contributed a somewhat different pro-thrombotic phenotype.
However, a sensitivity analysis excluding pro-thrombotic and
inflammation principal components estimated in the MESA study
yielded comparable results.
In European Americans, we identified 606 SNPs representing
19 loci that were associated with at least one metabolic trait
domain (Table 1, Figure 2) at the genome-wide significance level
(P,2.13610
27; the SNP with the lowest P – value chosen if
multiple significant SNPs were identified for a given locus) and
these results were consistent across the multiple large cohorts
(Table S10 and Figure S1). Several of these loci overlapped results
in African Americans (Table 2, Figure 3), including associations
with LPL, ABO, VWF, CTEP, and LDLR. In addition to these 19
loci, we also identified 15 additional secondary signals in European
Americans, defined as genome-wide significant SNPs (the SNP
with the lowest P – value chosen if multiple significant SNPs were
identified for a given locus) in very low linkage disequilibrium (LD)
(r
2,0.05) with the most significant SNP and within the same
1,000-kb region (Table S11). To verify the independent contribu-
Metabolic Phenotype Dimensions GWAS
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using the most significant SNP at each significant locus as a
covariate. Thirteen of these signals remained significant, including
one APOC1 variant, after adjusting for the primary signals.
Previously identified loci associated with single
metabolic trait domains
The strongest signal for both European American and African
American participants was located on chromosome 9 in the ABO
gene (P,1.0610
2300 and P=6.1610
275, respectively). These
signals overlap earlier findings between factor VIII and von
Willebrand factor with ABO [20]. Nine additional loci in European
Americans and eight loci in African Americans demonstrated
effects limited to one metabolic syndrome trait domain that have
already been reported in the GWA literature and are therefore not
considered further: ABCA1, APOB, CD36, CELSR2, CETP, CRP,
F7, LDLR, LIPC, PVRL2, TRIB1, VWF, and ZNF259.
Previously identified loci associated multiple trait
domains
Six loci were associated with at least two trait domains in
European Americans: GCKR, ABCB11, LPL, HNF1A, FTO, and
SUGP1, results which overlap published associations identified
through GWA studies for individual trait components. For
example, several GWA studies have identified associations
between GCKR and elevated plasma glucose [21], atherogenic
dyslipidemia [22], and vascular inflammation [23–25]. GCKR is a
plausible unifying mechanism for the clustering of metabolic
domains, as the protein inhibits glucokinase, the predominant
glucose phosphorylating enzyme [26]. HNF1A, which encodes the
transcription factor hepatocyte nuclear factor (HNF)-1a, also
suggests a common pathogenic background, as previous GWA
studies have identified associations with atherogenic dyslipidemia
[27], vascular inflammation [28], and type 2 diabetes [29]. Of
note, FTO was the only previously identified and consistently
replicated obesity locus we identified.
Candidate genes at new loci
The strongest new pleiotropic signal in European Americans
was for rs4420638 (P 1.7610
257), located approximately 0.32
kilobases (kb) downstream of APOC1 and associated with elevated
Figure 1. Variables used to characterize six metabolic syndrome domains.
doi:10.1371/journal.pgen.1002322.g001
Author Summary
The metabolic syndrome represents a clustering of
metabolic phenotypes (e.g. elevated blood pressure,
cholesterol levels, and plasma glucose, as well as
abdominal obesity) and is associated with an increased
risk of atherosclerosis and type 2 diabetes. Although
multiple genes influencing the specific metabolic syn-
drome components have been reported, few studies have
evaluated the genetic underpinnings of the syndrome as a
whole. Here, we describe an approach to evaluate multiple
clustered traits, which allows us to test whether common
genetic variants influence the co-occurrence of one or
more metabolic phenotypes. By examining approximately
20,000 European American and 6,200 African American
participants from five studies, we show that three regions
on chromosomes 12, 19, and 20 are associated with
multiple metabolic phenotypes. These genetic variants are
highly intriguing candidates that may increase our
understanding of the biologic basis of the clustering of
metabolic phenotypes and help identify targets for early
intervention.
Metabolic Phenotype Dimensions GWAS
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24), atherogenic dyslipidemia
(1610
231), vascular inflammation (P=5 610
212), and central
obesity (P=1.2610
26). Although associations between APOC1
with atherogenic dyslipidemia [22,30,31] and vascular inflamma-
tion [32,33] have been reported and replicated in the GWA study
literature, we consider it a novel locus due to the strong and
previously unreported associations with elevated plasma glucose
and central obesity. Localizing this signal is challenging, as the
region contains a 48-kb gene cluster that also includes the APOE
and pseudo-APOC’ genes [34]. However, the modest levels of
linkage disequilibrium (Figure 4), the presence of a second signal
(Table S11), studies which demonstrate that mice overexpressing
human APOC1 show a marked reduction in the update of fatty
acids into adipocytes [35], and the fact the physiological role of
APOC1 is less well established than APOE, APOB, and APOA1 [36]
all support further evaluation and fine mapping of APOC1.
The second new locus was rs11065987 (P=2.9610
210), located
approximately 9.9 kb upstream of BRAP and associated with
atherogenic dyslipidemia (3.1610
23), vascular dysfunction
(2.2610
24), and central obesity (9.7610
23). Initial reports
suggested that the BRAP protein binds the breast cancer
suppressor protein BRCA1 [37]. BRAP is also known to modulate
mitogen activated protein kinase signaling [38], an established cell
survival, growth, differentiation, transformation, and proinflam-
matory pathway [39].
The GWA study literature provides few clues that link BRAP
with metabolic trait domains, as associations have only been
identified for alanine aminotransferase [24] and esophageal cancer
[40], both in populations of Japanese descent. However, the
recombination rate (cM/Mb) is low from approximately 110.3 Mb
to 111.5 Mb (Figure 4) and this extended region includes loci
associated with type 1 diabetes [41,42], vascular dysfunction [43],
and waist-hip ratio [44]. The ATXN2 gene, located 27 kb from the
index SNP, is an intriguing candidate gene. Expansion of a CAG
repeat in the ataxin-2 protein causes the neurodegenerative disease
spinocerebellar ataxia type 2. However, instead of a neurodegen-
erative phenotype, ATXN2-deficient rodents exhibited phenotypes
characterized by abdominal obesity, insulin resistance, and
marked hepatosteatosis (i.e. lipid accumulation in the liver) [45].
Linkage studies of obesity in humans have also associated this
region with BMI and total fat percentage [46].
A third genome-wide significant signal was identified for
rs753381 (P=4.3610
28), a missense mutation in PLCG1 that
results in a change from an isoleucine to a threonine. PLCG1
encodes a protein that catalyzes the formation of inositol 1,4,5-
trisphosphate and diacylglycerol from phosphatidylinositol 4,5-
bisphosphate and plays an important role in the intracellular
transduction of receptor-mediated tyrosine kinase activators [47].
Few epidemiologic studies of PLCG1 or neighboring genes have
been published. However, mice nullizygous for PLCG1 stop
growing mid-gestation and show no evidence of vasculogenesis
[48]. Vasculogenesis has been associated with insulin resistance
[49], plasminogen activator inhibitor-1(PAI-1) concentration [50],
hyperglycemia, and adiponectin levels [51]. This suggests that
Figure 2. Multivariate association scan of the metabolic syndrome in n=19,468 European American participants from five cohorts.
Y-axis P–values are truncated at 1610
220.
doi:10.1371/journal.pgen.1002322.g002
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PLoS Genetics | www.plosgenetics.org 5 October 2011 | Volume 7 | Issue 10 | e1002322PLCG1 may contribute to the clustering of metabolic domains in a
more subtle manner, such as through small alterations in the
structure of the PLCG1 protein. Thus, the missense mutation we
identified would serve as a highly intriguing candidate SNP for
further study.
Discussion
In this study composed of approximately 20,000 European
American and 6,200 African American participants, we identified
three new loci associated with multiple metabolic trait domains:
APOC1, BRAP, and PLCG1. These loci were in or near genes
previously associated with atherogenic dyslipidemia, vascular
inflammation, type I diabetes, vascular dysfunction, and central
adiposity. No previous genome-wide or gene-centric studies
examining evidence for pleiotropy in metabolic domains has
detected these loci at genome-wide significant levels.
The pathogenesis of the clustering of metabolic phenotypes
remains poorly understood, althou g hi ti sl i k e l yt h a tas e d e n t a r y
lifestyle, combined with dietary patterns and genetic suscepti-
bility factors, contribute. Candidate genes associated with
metabolic syndrome phenotypes largely reflect current knowl-
edge of established pathways regulating obesity, free fatty acid
metabolism, insulin sensitivity, lipid metabolism, and inflam-
mation. Although candidate gene and GWA studies have
successfully identified loci influencing variation in these
pathways, studies examining genetic factors influencing the co-
occurrence of metabolic phenotypes are limited. Additionally,
those that examine the clustering of syndromic components
using the pre-defined clinical cutpoints are largely inconsistent
or inconclusive. This general lack of success may reflect ongoing
controversy over metabolic syndrome definitions, leading to
phenotypic heterogeneity and inconsistent genetic findings
across studies [52]. The utility of studying the syndrome as a
binary entity as opposed to a series of component traits is also
debated [12], especially since the dichotomization of interval
scale traits will discard information.
Methods for examining evidence of pleiotropy remain uncom-
mon in the GWA literature and most likely reflect the lack of
methodologies and software that are scalable to GWA studies. In
this paper, we present a statistically efficient and computational
feasible approach to testing for pleiotropy on a genome-wide scale.
Our method is applicable to population-based and family studies
and identified several associations that would not have been
identified through typical univariate analyses. The approach
presented herein is also not limited to metabolic phenotypes.
Instead, our method could be applied to any set of interval scale
traits that are heritable and exhibit evidence of phenotypic
clustering.
Although alternative analytic approaches were available, for
example estimating principal components for all traits simulta-
neously, we focused on the phenotype clusters presented in
Figure 1. First, evaluating the nineteen phenotypes of interest as
six domains of interest is biologically plausible given evidence of
phenotypic clustering. It was also easier to interpret principal
components that were derived in separate phenotype domains
rather than components estimated simultaneously. Additionally,
estimating principal components within each phenotype domains
ensured that each domain was sufficiently represented in the
analysis.
Challenges to the approach presented herein include careful
phenotype curation, made more difficult by the inclusion of 19
traits across multiple cohorts that were not measured with a
common protocol. Only the ARIC and CARDIA studies had full
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study with all traits measured during a single visit. The use of a
multivariate phenotype comprised of 19 variables also limited the
number of contributing cohorts and the identification of
replication cohorts, as few studies have such comprehensive
phenotypic data. Nonetheless, we were able to identify approx-
imately 25,000 participants from studies that used standardized,
comparable protocols and many of the associations were consistent
across cohorts.
Further challenges that are not unique to large scale genetic
studies incorporatinga phenomicsapproachinclude the consistency
of results across populations defined by age, race, sex, or other
demographic characteristics. For example, the three new loci
identified in the European American population were not detected
in the African American population. Given a modest sample size of
6,287 participants it is difficult to determine whether an inability to
generalize results to the African American population reflects
different patterns of LD, varying environmental contexts, or limited
statistical power. Variation in mean age between contributing
cohorts, which ranged from 25 years in the CARDIA study to 72
years in the CHS, could introduce additional heterogeneity, as
associations between metabolic phenotypes have been shown to
diminish with age [53]. Finally, marked variation in the prevalence
of the metabolic syndrome by gender, regardless of clinical
definition, suggest the possibility of sex-specific metabolic syndrome
effects [54]. Analyses that examine modification by sex, age, and
other important clinical covariates are therefore warranted.
Our use of the IBC array, which is composed of variants
implicated in cardiovascular, inflammatory, hemostasis/coagulation,
and metabolic pathways, was beneficial in that it allowed us to
leverage the wealth of information on pathways implicated in
metabolic disturbances while reducing multiple testing penalties.
Admittedly this approach was limited in that it potentially excludes
novel pathways not captured by the IBC chip. Although imputation
allowed us to increase the number of variants, genome-wide
approaches might identify additional pleiotropic loci.
In summary, our results support phenomics as a complementary
approach that leverages phenotypic variation for the evaluation of
pleiotropy, a clear limitation of existing studies examining the
metabolic syndrome using clinical definitions. Our approach,
which is applicable to studies of heritable, clustered interval scale
outcomes, also takes advantage of the wealth of phenotype data
available in longitudinal cohort studies as well as emerging
analytical and bioinformatics approaches. Ultimately, these results
support the presence of genetic variants with pleiotropic effects on
adiposity, inflammation, glucose regulation, dyslipidemia, vascular
dysfunction and thrombosis. Such loci may help characterize
metabolic dysregulation and identify targets for intervention.
Materials and Methods
Study population
This study arose from a collaboration between investigators
from two National Institute of Health funded consortia examining
Figure 3. Multivariate GWAS of metabolic syndrome in n=6,287 African American participants from four cohorts. Y-axis P–values
are truncated at 1610
220.
doi:10.1371/journal.pgen.1002322.g003
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PLoS Genetics | www.plosgenetics.org 8 October 2011 | Volume 7 | Issue 10 | e1002322the genetic basis of common complex diseases: the Population
Architecture using Genomics and Epidemiology (PAGE) study, a
National Human Genome Research Institute funded effort
examining the epidemiologic architecture of common genetic
variation that have been reproducibly associated with human
diseases and traits [55] and the CARe Consortium [56], a
National Heart, Lung, and Blood Institute-supported resource for
genetic analyses examining cardiovascular phenotypes. Briefly,
PAGE investigators participating in the phenomics working group
wanted to extend existing efforts examining evidence for
pleiotropy in approximately 300 replicated genetic variants [57]
to include a more comprehensive evaluation of common SNPs. A
collaboration between PAGE and CARe investigators was
therefore initiated, and used data from five CARe studies of
European American and African American with adequate
phenotype data: ARIC, CARDIA, CHS, FHS, and MESA. All
participating institutions and CARe sites obtained Institutional
Review Board approval for this study. Additional information on
the participating CARe studies is provided in Text S1.
Genotyping
The Institute for the Translational Medicine and Therapeutics
(ITMAT)-Broad-CARe (IBC) genotyping array [58] was used to
evaluate approximately 2,100 genes related to cardiovascular,
inflammatory, hemostasis/coagulation, and metabolic phenotypes
and pathways. The IBC array tagging approach was designed to
capture maximal genetic information for both common and lower
frequency SNPs (,5% minor allele frequency (MAF)) in HapMap
as well as European American and African American populations.
The array included 49,320 SNPs, 15,000 of which were gene
variants not present in HapMap. Additional details of the SNP
selection and tagging approach are given in Text S1.
Imputation of untyped and missing SNP genotypes was
performed using MACH 1.0.16. [59] For the European samples,
phased haplotypes from the CEU founders of HapMap 2 were
used as reference. For African American populations, a combined
CEU+YRI reference panel was created that includes SNPs
segregating in both CEU and YRI, as well as SNPs segregating
in one panel and monomorphic and non-missing in the other.
Imputation for the IBC array was performed in two steps. First,
individuals with pedigree relatedness or cryptic relatedness were
filtered. A subset of individuals was randomly extracted from each
panel and used to generate recombination and error rate estimates
for the corresponding sample. Second, these rates were used to
impute all sample individuals across the entire reference panel.
Before cleaning, there were an average of 246,740 (range:
245,816, 247,505) and 227,224 (range: 225,111, 229,061) imputed
SNPs in the European American and African American study
populations, respectively. Imputation results were then filtered at
an imputation quality limit of 0.30 and a MAF threshold of 0.01,
yielding 235,077 (95.3% of total) and 227,222 (96.2% of total)
SNPs for analysis in European American and African American
participants, respectively.
Phenotypes
The clustered risk factors of interest were characterized as a six-
domain phenotype: atherogenic dyslipidemia, vascular dysfunc-
tion, vascular inflammation, pro-thrombotic state, elevated plasma
glucose, and central obesity (Figure 1). These domains were
constructed a priori based on a review of literature examining
clustering in metabolic phenotypes, placing specific emphasis on
the National Cholesterol Education Program’s Adult Treatment
Panel III report [4,60]. Nineteen variables were then selected to
represent one of the six domains with preference for variables
measured in at least four of the contributing cohort studies or
variables that were highly correlated with available measures.
Measurement protocols for each variable by study are provided in
Table S21. We assessed normality, and transformations were used
when variables exhibited excessive skewness or kurtosis as
determined by numerical summary information and visual
inspection of histograms and normal probability plots. Dimension
reduction using principal components analysis was then performed
for each phenotype domain separately in each race/ethnic and
study population. For example, principal components for the
vascular inflammation domain were calculated using the following
traits: albumin, C reactive protein, fibrinogen, uric acid, and white
blood cell count. Principal components were chosen so that.55%
of the variance for each domain was explained (Tables S12, S13,
S14, S15, S16, S17, S18, S19, S20). This threshold was chosen
because all of the first (waist circumference, pro-thrombotic state,
elevated plasma glucose, and vascular dysfunction) and the sum of
first and second (vascular inflammation and atherogenic dyslipi-
demia) principal components exceeded 55% across all studies and
racial/ethnic groups.
Statistical methods
For each phenotype, we fit a linear regression model relating the
phenotype to the SNP genotype under the additive mode of
inheritance; the model includes environmental variables (i.e., age, sex
and study center) as well as the first ten principal components from
EIGENSTRAT to adjust for population substructure [61]. Ten
population substructure components were included because each
component was associated with at least one of the eight phenotypes of
interest in at least one study. If the SNP genotype is not associated with
any phenotype domain, then the regression coefficients for the SNP
genotype are zero in all eight linear models. We tested this global null
hypothesis by constructing a multivariate test statistic based on the joint
distribution of the score statistics from the eight linear models, which
accounted for the correlation between the eight phenotypes. We chose
the score statisticbecause it iscomputationally efficient and numerically
stable. The test statistic is referred to the chi-squared distribution with
eight degrees of freedom. The genome-wide significance level was set
as P,2.13610
27 (i.e. 0.05/235,077). Q-Q plots by race are not
presented, as our use of a gene-centric array highly enriched for
metabolic loci complicated the identification of markers with low prior
probabilities of association (i.e. ‘‘nu l lm a r k e r s ’ ’ )f o ra l lp h e n o t y p e so f
interest. The data from each cohort were analyzed separately and the
Figure 4. Regional association plots for metabolic syndrome trait dimensions associated with APOC1, BRAP, and PLCG1. Positions are
from NCBI build 36 and recombination rates are estimated from HapMap phase II CEU data. SNPs are represented by circles, and the large blue
diamond is the SNP with the lowest P-value. Circle color represents correlation with the top SNP: blue indicates weak correlation and red indicates
strong correlation. Recombination rate is plotted in the background and known genes in the region are shown at the bottom of the plot.
doi:10.1371/journal.pgen.1002322.g004
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analyses were stratified by race and were performed in SAS 9.1 and
C++. Further details are given in the Text S2.
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